Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family

  • Bioorg Med Chem Lett. 2012 Sep 1;22(17):5352-9. doi: 10.1016/j.bmcl.2012.06.053.
M Raymond V Finlay  1 ,  Roger J Griffin
Affiliations
  • 1. AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
PMID: 22835870 DOI: 10.1016/j.bmcl.2012.06.053
Abstract

Modulation of DNA repair pathways in oncology has been an area of intense interest in the last decade, not least as a consequence of the promising clinical activity of poly(ADP-ribose) polymerase (PARP) inhibitors. In this review article, we highlight inhibitors of the phosphatidylinositol 3-kinase related kinase (PIKK) family as of potential interest in the treatment of Cancer, both in combination with DNA-damaging therapies and as stand-alone agents.